Charles River Laboratories International Inc. (NYSE: CRL) Stock News & Analysis
Charles River Laboratories International Inc. (NYSE: CRL) is a healthcare company, listed on the NYSE. Alpha Stocks Insight tracks CRL across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 1 article published since May 7, 2026, providing investors with timely, data-driven analysis of Charles River Laboratories International Inc.'s financial performance and competitive position. New coverage is added each trading day.
CRL Coverage -- 1 Article
Charles River Laboratories (NYSE: CRL) Beats Q1 2026 EPS Estimates, Reaffirms Full-Year Guidance
CRL posted Q1 EPS of $2.06 and revenue of $995.8M, topping Wall Street estimates. Full-year guidance was reaffirmed amid ongoing portfolio reshaping.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.